All eyes on Regeneron Q4 results with focus on blockbusters Dupixent, Eylea
Sharamand/iStock via Getty Images

Regeneron Pharmaceuticals (NASDAQ:REGN) is scheduled to announce Q4 earnings results on Friday, February 3rd, before market open.
The consensus EPS Estimate is $10.01 (-57.8% Y/Y) and the consensus Revenue Estimate is $3.11B (-37.2% Y/Y).
Over the last 2 years, REGN has beaten EPS estimates 100% of the time and has beaten revenue estimates 88% of the time.
Over the last 3 months, EPS estimates have seen 6 upward revisions and 12 downward. Revenue estimates have seen 6 upward revisions and 10 downward.
The company's stock was largely flat on Nov. 3 (-0.24%) after Q3 results beat estimates. Q3 revenues excluding COVID-19 therapies grew as blockbusters Eylea and Dupixent drove up sales.
For Q4, Regeneron has already announced a $0.21 impact to GAAP and non-GAAP net income per diluted share due to a one-off R&D charge. Regeneron had attributed the impact to a licensing agreement with CytomX Therapeutics to to develop cancer drugs.

In January, Cowen upgraded Regeneron to Outperform from Market Perform citing the long-term potential of the eye disease therapy Eylea, the biotech markets with Bayer. The drug's high-dose version had showed noninferiority to the standard 2mg dose along with less frequent administration.
The company also saw an upgrade at JPMorgan, on several key catalysts in 2023, including the upcoming launch of high-dose Eylea.
Regeneron's other blockbuster drug Dupixent, developed and sold with Sanofi, has also been gaining ground by getting approvals in additional indications in the EU.
However, in December 2022, the U.K. drug regulator warned patients of risks of ocular adverse reactions after treatment with Dupixent.
Meanwhile, cancer Libtayo also received expanded use approvals in the EU and Japan.
Regeneron also received the FDA's priority review for expanding Evkeeza use for children aged 5 to 11 years with homozygous familial hypercholesterolemia.
In November 2022, The U.S. Supreme Court decided to hear an appeal filed by Amgen over a lower court's decision to invalidate key patents on its cholesterol drug Repatha following a challenge by Sanofi and Regeneron.